Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Role in Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients \> 18 years old hospitalized with acute kidney injury and anemia~Exclusion Criteria:~* pregnant women, terminally ill patients, patients with major or minor thalassemia, patients with stable chronic kidney disease or patients on dialysis and patients who were receiving rHuEPO or any erythropoiesis-stimulating agent (ESA) before admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
- Group 2 (Type: NO_INTERVENTION): No recombinant human erythropoietin will be administered to this group

Based on this trial design, predict the completion outcome and termination type (if applicable).